Education
About Us
Working with TipRanks
Follow Us
Sprint Bioscience AB (SE:SPRINT)
:SPRINT
SPRINT Stock Chart & Stats
kr1.42
-kr0.03(-2.43%)
At close: 4:00 PM EST
kr1.42
-kr0.03(-2.43%)
Day’s Range― - ―
52-Week Rangekr0.36 - kr1.93
Previous CloseN/A
Volume19.16K
Average Volume (3M)560.98K
Market Cap
kr152.47M
Enterprise Valuekr49.83M
Total Cash (Recent Filing)kr10.95M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Feb 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding105,515,540
10 Day Avg. Volume1,502,692
30 Day Avg. Volume560,983
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)11.75
Price to Sales (P/S)1.66
P/FCF Ratio-4.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
SPRINT FAQ
What was Sprint Bioscience AB’s price range in the past 12 months?
Sprint Bioscience AB lowest stock price was kr0.36 and its highest was kr1.93 in the past 12 months.
What is Sprint Bioscience AB’s market cap?
Sprint Bioscience AB’s market cap is kr152.47M.
When is Sprint Bioscience AB’s upcoming earnings report date?
Sprint Bioscience AB’s upcoming earnings report date is Feb 11, 2026 which is in 47 days.
How were Sprint Bioscience AB’s earnings last quarter?
Sprint Bioscience AB released its earnings results on Nov 25, 2025. The company reported -kr0.08 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.08.
Is Sprint Bioscience AB overvalued?
According to Wall Street analysts Sprint Bioscience AB’s price is currently Overvalued.
Does Sprint Bioscience AB pay dividends?
Sprint Bioscience AB does not currently pay dividends.
What is Sprint Bioscience AB’s EPS estimate?
Sprint Bioscience AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sprint Bioscience AB have?
Sprint Bioscience AB has 105,515,540 shares outstanding.
What happened to Sprint Bioscience AB’s price movement after its last earnings report?
Sprint Bioscience AB reported an EPS of -kr0.08 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.167%.
Which hedge fund is a major shareholder of Sprint Bioscience AB?
Currently, no hedge funds are holding shares in SE:SPRINT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sprint Bioscience AB
Sprint Bioscience AB (SPRINT) is a biotechnology company based in Sweden, specializing in the early-stage development of oncology therapeutics. The company focuses on the discovery and development of innovative small-molecule drug candidates targeting cancer metabolism and tumor immune evasion. Their leading programs are aimed at addressing unmet medical needs in cancer treatment by advancing proprietary projects through preclinical phases, with the ultimate goal of out-licensing them to pharmaceutical partners for further development and commercialization.
Technical Analysis
2cureX AB
―
Scandinavian ChemoTech AB Class B
―
LIDDS AB
―
ExpreS2ion Biotech Holding AB
―
CombiGene AB
―